CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Ultragenyx Pharmaceutical Inc. (RARE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Ultragenyx Pharmaceutical Inc. (RARE)

Pharmaceutical Preparations · market cap $1.5B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-01-15 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Ultragenyx (RARE) is a rare and ultra-rare genetic disease developer working across biologics, small molecules, gene therapy, ASOs and mRNA in bone, endocrine, metabolic, muscle and CNS indications. It has 893 employees, a ~$1.59B market cap at ~$16.08 per share, and a late-stage pipeline led by GTX-102 (Phase 3, Angelman Syndrome). Our calendar shows two high-importance Phase 3 events in the next ~10 months (setrusumab and triheptanoin), against a reported 9-month cash runway.
The catalyst path
  • 2027-01-15 (est.)Phase 3 · setrusumabimp 9/10
  • 2027-08-15 (est.)Phase 3 · Triheptanoinimp 9/10
Pipeline
AssetPhaseIndication
aceneuramic acid extended-release (Ace-ER)Phase 3Hereditary Inclusion Body Myopathy
UX111Phase 3MPS IIIA
Sialic Acid Extended Release (SA-ER)Phase 2GNE Myopathy
SA-ERPhase 2GNE Myopathy
UX003Phase 3MPS 7
BPS804Phase 2Hypophosphatasia
steroid regimenPhase 2GSD1
Oral CorticosteroidsPhase 3OTC Deficiency
Reactive Corticosteroid Taper RegimenPhase 2Ornithine Transcarbamylase (OTC) Deficiency
BisphosphonatePhase 3Osteogenesis Imperfecta
GTX-102Phase 3Angelman Syndrome
Standard of Care (SOC)Phase 2Wilson Disease
UX007Phase 2Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
TriheptanoinPhase 3Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Oral prednisolonePhase 3Glycogen Storage Disease Type IA
setrusumabPhase 3Osteogenesis Imperfecta, Type I
BurosumabPhase 3Hypophosphatemia
[6,6-2H2]glucosePhase 2Glycogen Storage Disease Type IA
POST TriheptanoinPhase 2Frontal Lobe Hypometabolism
Triheptanoin oilPhase 2Huntington Disease
Price & technical context
3-month
-36.5%
6-month
-33.1%
12-month
-50.8%
52-wk range
$12.88–$36.54
vs 50-day MA
+5.8%
vs 200-day MA
-28.0%
Realized vol
96.8%
Max drawdown
-76.5%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for RARE (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.